Literature DB >> 8428344

Prostate cancer. Radiation therapy for localized disease.

M A Bagshaw1, I D Kaplan, R C Cox.   

Abstract

BACKGROUND: Since 1910, a variety of radiation modalities, including radioactive isotopes, photons, and particle beams, have been used to treat prostatic cancer.
METHODS: This report focuses on external beam x-irradiation produced by medium energy linear accelerators. Between 1956 and 1990, 1119 patients have been treated with curative intent at Stanford University. Tumor doses of 70 Gy delivered at 10 Gy/wk have been safe and effective.
RESULTS: Fifteen-year survival rates ranging from 50%, equivalent to that of an age-matched cohort, for the least extensively localized tumors to 18% for the most extensive have been achieved. Survival is inversely proportional to clinical stage and histopathologic grade.
CONCLUSION: Although external beam radiation therapy has been found to be safe and effective for the treatment of prostatic cancer, improvement in results of treatment of the more advanced tumors might be achieved by combining external beam and interstitial irradiation. This would achieve a higher radiation dose within the tumor. Alternatively, the treatment can be augmented with hyperthermia or other sensitizers in order to achieve a higher biological dose.

Entities:  

Mesh:

Year:  1993        PMID: 8428344     DOI: 10.1002/1097-0142(19930201)71:3+<939::aid-cncr2820711409>3.0.co;2-0

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  12 in total

Review 1.  Localised carcinoma of the prostate: a paradigm of uncertainty.

Authors:  S S Sandhu; A V Kaisary
Journal:  Postgrad Med J       Date:  1997-11       Impact factor: 2.401

Review 2.  The efficacy of conventional external beam, three-dimensional conformal, intensity-modulated, particle beam radiation, and brachytherapy for localized prostate cancer.

Authors:  Tony Y Eng; Join Y Luh; Charles R Thomas
Journal:  Curr Urol Rep       Date:  2005-05       Impact factor: 3.092

3.  Three dimensional conformal radiotherapy in patients with T2a-b, N0, M0 prostatic carcinoma.

Authors:  C Kurtman; B Celebioğlu; O Göğüş; M N Andrieu
Journal:  Int Urol Nephrol       Date:  2000       Impact factor: 2.370

4.  Iridium 192 high-dose-rate brachytherapy--a useful alternative therapy for localized prostate cancer?

Authors:  R Paul; R Hofmann; J U Schwarzer; R Stepan; H J Feldmann; P Kneschaurek; M Molls; R Hartung
Journal:  World J Urol       Date:  1997       Impact factor: 4.226

Review 5.  Management strategies for locally advanced prostate cancer.

Authors:  Ashesh B Jani
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

6.  The dilemma of hereditary prostate cancer.

Authors:  J C Nickel
Journal:  CMAJ       Date:  1995-10-01       Impact factor: 8.262

7.  Docetaxel and bortezomib downregulate Bcl-2 and sensitize PC-3-Bcl-2 expressing prostate cancer cells to irradiation.

Authors:  Wengang Cao; Kathleen T Shiverick; Kazunori Namiki; Yoshihisa Sakai; Stacy Porvasnik; Cydney Urbanek; Charles J Rosser
Journal:  World J Urol       Date:  2008-07-02       Impact factor: 4.226

8.  An exercise trial to reduce cancer related fatigue in African American breast cancer patients undergoing radiation therapy: Design, rationale, and methods.

Authors:  Chiranjeev Dash; Pamela D Randolph-Jackson; Claudine Isaacs; Mary Mills; Kepher Makambi; Vivian V Watkins; Lucile L Adams-Campbell
Journal:  Contemp Clin Trials       Date:  2016-01-18       Impact factor: 2.226

Review 9.  Molecular fingerprinting of radiation resistant tumors: can we apprehend and rehabilitate the suspects?

Authors:  Charles J Rosser; Micah Gaar; Stacy Porvasnik
Journal:  BMC Cancer       Date:  2009-07-09       Impact factor: 4.430

Review 10.  Radiotherapy for t3 prostate cancer.

Authors:  Andrew Bayley; Mary K Gospodarowicz
Journal:  Curr Urol Rep       Date:  2003-06       Impact factor: 2.862

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.